Published in Ann Pharmacother on February 14, 2006
Preventing deep wound infection after coronary artery bypass grafting: a review. Tex Heart Inst J (2013) 0.95
Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery. Infect Control Hosp Epidemiol (2011) 0.88
Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother (2007) 0.88
Kytococcus schroeteri: a probably underdiagnosed pathogen involved in prosthetic valve endocarditis. Wien Klin Wochenschr (2008) 0.84
Surgical site infection prophylaxis strategies for cardiothoracic surgery: a decision-analytic model. Scand J Infect Dis (2012) 0.75
Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis. Support Care Cancer (2008) 0.75
Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer (2014) 1.98
Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther (2006) 1.84
Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. Am J Crit Care (2002) 1.72
Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother (2010) 1.69
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.63
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother (2006) 1.62
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol (2007) 1.41
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother (2012) 1.33
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis (2008) 1.15
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis (2007) 1.14
Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. Pharmacotherapy (2007) 1.14
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol (2014) 1.12
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol (2009) 1.10
Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother (2012) 1.06
Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother (2012) 1.05
Involvement of immunization-certified pharmacists with immunization activities. Ann Pharmacother (2003) 1.05
Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother (2006) 1.01
Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis (2009) 0.99
The transition from open to endoscopic saphenous vein harvesting and its clinical impact: The Texas Heart Institute experience. Tex Heart Inst J (2006) 0.99
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther (2005) 0.97
An efficient light-driven P450 BM3 biocatalyst. J Am Chem Soc (2013) 0.96
Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis (2012) 0.91
A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy. Am J Pharm Educ (2013) 0.90
Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci (2003) 0.87
Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses (2011) 0.87
In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health (2011) 0.87
Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai (2011) 0.86
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin (2007) 0.84
Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria. Ann Pharmacother (2012) 0.83
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother (2013) 0.82
Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs (2010) 0.82
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther (2010) 0.81
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol (2014) 0.81
Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother (2010) 0.80
Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol (2012) 0.79
Reducing the incidence of nosocomial pneumonia in cardiovascular surgery patients. Qual Manag Health Care (2003) 0.79
Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians. Am J Health Syst Pharm (2010) 0.79
Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses (2006) 0.79
Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV AIDS (Auckl) (2013) 0.79
Impact of a pharmacotherapy alerting system on medication errors. Am J Health Syst Pharm (2013) 0.78
Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother (2006) 0.78
Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol (2010) 0.78
Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother (2010) 0.77
Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci (2009) 0.77
Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm (2012) 0.77
Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis (2013) 0.77
Clostridium difficile-related death rates in Texas 1999-2005. J Infect (2009) 0.77
Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.77
Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm (2011) 0.77
Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci (2012) 0.77
Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother (2014) 0.76
Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. Diagn Microbiol Infect Dis (2002) 0.76
A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy (2012) 0.76
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol (2017) 0.75
Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia (2014) 0.75
Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies. Curr Infect Dis Rep (2008) 0.75
An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm (2006) 0.75
Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm (2010) 0.75
Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm (2008) 0.75
Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. Pharmacotherapy (2008) 0.75
Pilot of a patient-centered pharmacy practice model. Am J Health Syst Pharm (2012) 0.75
Pharmacists' perceptions of the effectiveness of antimicrobial control programs. Am J Health Syst Pharm (2006) 0.75
Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci (2005) 0.75